Replies to post #6532 on International Stem Cell Corp. (ISCO)

[MinnieM]

Why ISCO is running trials in Australia.

ISCO isn't a scam company. They have two subsidiaries bringing in revenue. But, research and trials are very expensive. Cost is why many companies are running clinical trials in Australia. Go to the links I've provided rather than just reading the titles.

I'm sure you've heard of astrazeneca. Here's their take on doing trials in Australia.
https://www.astrazeneca.com.au/sustainability/About-us-research-development.html

In partnership with doctors in Australia we focus our skills and resources on getting life-changing medicines to patients as quickly, safely and efficiently as possible. We are currently conducting research to develop new medicines in the following disease areas:

To find out more about clinical trials in Australia, please visit the dedicated Australian Government website www.australianclinicaltrials.gov.au

**********

HTTPS://WWW.OUTSOURCING-PHARMA.COM/ARTICLE/2019/04/29/AUSTRALIA-S-CLINICAL-TRIALS-INDUSTRY-IS-EXPERIENCING-UNPRECEDENTED-SUPPORT

Australia’s clinical trials industry is experiencing ‘unprecedented support’
29-Apr-2019 By Melissa Fassbender

The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.

**********

Australia: Preferred Destination for Early Phase Clinical Trials
https://ww3.frost.com/files/6514/7374/3781/Novotech_WP_20160701_v2.1.pdf

**********

As I said earlier, dilution has been the main problem here. Not unheard of in biotech. Biotech is very risky for early investors and I got involved way too early with this one. But, that is my fault, not the company's fault. It's been off my radar for awhile now, but, I'm watching again for the upcoming trial results.

[Doctor_Hari_Seldon]

The FDA does some good things, but they also force a lot of bullshit and costs that get in the way of human trials. ISCO went to Australia to avoid all that and get their therapeutic into 12 humans as soon as practical. All 12 had well tolerated procedures which is great. The FDA also considers safety and efficacy data from credible institutions around the world, such as the Florey Institute of Neuroscience in Australia, when evaluating further studies along the same or related lines.